Celsion Corp. Company Profile (NASDAQ:CLSN)

About Celsion Corp.

Celsion Corporation is an oncology drug development company. The Company's product candidate is ThermoDox, a heat-activated liposomal encapsulation of doxorubicin, which is in Phase III clinical trial for treatment of primary liver cancer (the OPTIMA Study) and a Phase II clinical trial for treatment of recurrent chest wall breast cancer (the DIGNITY Study). Its pipeline also includes GEN-1, a deoxyribonucleic acid (DNA) mediated immunotherapy for the localized treatment of ovarian and brain cancers. It has over three platform technologies for the development of treatments for those suffering with difficult-to-treat forms of cancer, including Lysolipid Thermally Sensitive Liposomes, a heat sensitive liposomal based dosage form that targets disease with known therapeutics in the presence of mild heat; TheraPlas, a nucleic acid-based treatment for local transfection of therapeutic plasmids, and TheraSilence, a systemic dosage form for lung directed anti-cancer ribonucleic acid (RNA).

Industry, Sector and Symbol:

• Sector: Medical
• Industry: Biotechnology
• Sub-Industry: N/A
• Exchange: NASDAQ
• Symbol: CLSN
• CUSIP:

Key Metrics:

• Previous Close: $1.26
• 50 Day Moving Average: $1.24
• 200 Day Moving Average: $1.36
• 52-Week Range: $25,810,000.00 - $1.04
• Trailing P/E Ratio: N/A
• Foreward P/E Ratio: -2.25
• P/E Growth: 0.00
• Market Cap: $32.52M
• Outstanding Shares: 25,810,000
• Beta: 2.36

Profitability:

• Net Margins: -3,966.14%
• Return on Equity: -103.07%
• Return on Assets: -42.02%

Debt:

• Current Ratio: 1.44%
• Quick Ratio: 1.44%

Additional Links:

• Visit Celsion Corp.'s Official Website
• View CLSN on Google Finance
• View CLSN on Yahoo Finance
• View CLSN's Company Profile on Reuters
• Search for Celsion Corp. on Google

Companies Related to Celsion Corp.:

• Sunesis Pharmaceuticals (NASDAQ:SNSS)
• Avinger (NASDAQ:AVGR)
• Biota Pharmaceuticals (NASDAQ:AVIR)
• Xoma Corp. (NASDAQ:XOMA)
• MEI Pharma (NASDAQ:MEIP)
• Catasys (OTCMKTS:CATS)
• Prima BioMed (NASDAQ:PBMD)
• Intellipharmaceutics International (NASDAQ:IPCI)
• Auris Medical Holding AG (NASDAQ:EARS)
• Calithera Biosciences (NASDAQ:CALA)

Earnings

Earnings History for Celsion Corp. (NASDAQ:CLSN)

Date	Quarter	Consensus Estimate	Actual EPS	Revenue Estimate	Actual Revenue	Release Link	Conference Call	Details
11/3/2016
8/15/2016	Q2	($0.21)	($0.19)			View	Listen
5/16/2016	Q116	($0.21)	($0.24)			View	Listen
3/30/2016	Q415	($0.24)	($0.24)			View	Listen
11/5/2015	Q315	($0.26)	($0.20)			View	N/A
8/10/2015	Q215	($0.31)	($0.27)			View	Listen
5/12/2015	Q1	($0.33)	($0.34)			View	N/A
3/12/2015		($0.36)	($0.32)			View	N/A
11/12/2014		($0.30)	($0.35)			View	N/A
8/7/2014	Q214	($0.32)	($0.38)			View	N/A
5/8/2014		($0.24)	($0.33)			View	N/A
3/13/2014		($0.28)	($0.19)			View	N/A
11/12/2013	Q3	($0.23)	($0.30)		$0.13 million	View	Listen
8/8/2013	Q2 2013	($0.07)	$0.01		$0.13 million	View	N/A
5/9/2013	Q1 2013	($0.16)	($0.12)			View	N/A
11/12/2012	Q312	($0.17)	($0.18)			View	N/A

(Data available from 1/1/2011 forward)

Estimates

Earnings Estimates for Celsion Corp. (NASDAQ:CLSN)

Quarter	Number of Estimates	Low Estimate	High Estimate	Average Estimate
Q1 2016	1	($0.22)	($0.22)	($0.22)
Q2 2016	1	($0.20)	($0.20)	($0.20)
Q3 2016	1	($0.17)	($0.17)	($0.17)
Q4 2016	1	($0.17)	($0.17)	($0.17)
Q1 2017	1	($0.15)	($0.15)	($0.15)
Q2 2017	1	($0.15)	($0.15)	($0.15)
Q3 2017	1	($0.11)	($0.11)	($0.11)
Q4 2017	1	($0.09)	($0.09)	($0.09)

(Data provided by Zacks Investment Research)

Dividends

Dividend History for Celsion Corp. (NASDAQ:CLSN)
No dividend announcements for this company have been tracked by MarketBeat.com

Insider Trades

Insider Trading History for Celsion Corp. (NASDAQ:CLSN)

Transaction Date	Insider Name	Title	Buy/Sell	Number of Shares	Average Share Price	Total Transaction	Details
8/16/2016	Alberto R Martinez Jr	Director	Buy	5,000	$1.25	$6,250.00
6/17/2016	Alberto R Martinez Jr	Director	Buy	5,000	$1.35	$6,750.00
6/16/2016	Michael H Tardugno	CEO	Buy	7,500	$1.35	$10,125.00
2/19/2016	Michael H Tardugno	CEO	Buy	3,000	$1.27	$3,810.00
2/17/2016	Michael H Tardugno	CEO	Buy	2,000	$1.27	$2,540.00
2/16/2016	Alberto R Martinez Jr	Director	Buy	5,000	$1.16	$5,800.00
2/16/2016	Michael H Tardugno	CEO	Buy	4,500	$1.20	$5,400.00
2/12/2016	Michael H Tardugno	CEO	Buy	6,500	$1.13	$7,345.00
12/3/2015	Egwu, Inc. Fka Egen, Inc.	Major Shareholder	Sell	5,556	$2.08	$11,556.48
11/30/2015	Egwu, Inc. Fka Egen, Inc.	Major Shareholder	Sell	20,000	$2.15	$43,000.00
9/8/2015	Egwu, Inc. Fka Egen, Inc.	Major Shareholder	Sell	10,000	$2.11	$21,100.00
8/17/2015	Egwu, Inc. Fka Egen, Inc.	Major Shareholder	Sell	10,000	$2.19	$21,900.00
8/13/2015	Egwu, Inc. Fka Egen, Inc.	Major Shareholder	Sell	20,000	$2.23	$44,600.00
5/13/2015	Alberto R Martinez Jr	Director	Buy	5,000	$2.50	$12,500.00
12/18/2014	Frederick J Fritz	Director	Buy	4,000	$2.34	$9,360.00
11/13/2014	Robert W Hooper	Director	Buy	4,000	$2.50	$10,000.00
8/15/2014	Alberto R Martinez Jr	Director	Buy	5,000	$3.12	$15,600.00
8/15/2014	Michael H Tardugno	CEO	Buy	4,000	$3.12	$12,480.00
8/14/2014	Frederick J Fritz	Director	Buy	4,000	$3.20	$12,800.00
6/26/2014	Alberto R Martinez Jr	Director	Buy	5,000	$3.36	$16,800.00
6/11/2014	Michael H Tardugno	CEO	Buy	5,000	$3.20	$16,000.00
3/14/2014	Frederick Fritz	Director	Buy	2,500	$3.86	$9,650.00
3/14/2014	Michael Tardugno	CEO	Buy	4,000	$3.84	$15,360.00
11/19/2013	Michael Tardugno	CEO	Buy	2,800	$3.59	$10,052.00
11/15/2013	Frederick Fritz	Director	Buy	3,000	$3.80	$11,400.00
8/16/2013	Frederick Fritz	Director	Buy	10,000	$1.09	$10,900.00
8/16/2013	Michael Tardugno	CEO	Buy	5,000	$1.08	$5,400.00
6/12/2013	Michael H Tardugno	CEO	Buy	10,000	$1.35	$13,500.00
5/21/2013	Alberto R Martinez Jr	Director	Buy	5,000	$0.93	$4,650.00
5/13/2013	Alberto R Martinez Jr	Director	Buy	5,000	$0.96	$4,800.00
5/10/2013	Alberto R Martinez Jr	Director	Buy	5,000	$0.92	$4,600.00
3/20/2013	Alberto R Martinez Jr	Director	Buy	3,750	$1.06	$3,975.00
12/10/2012	Max Link	Director	Buy	14,000	$7.60	$106,400.00
11/15/2012	Robert W Hooper	Director	Buy	11,600	$5.20	$60,320.00
9/14/2012	Michael H Tardugno	CEO	Buy	5,000	$5.03	$25,150.00
9/10/2012	Robert W Hooper	Director	Buy	10,000	$4.95	$49,500.00
8/29/2012	Robert W Hooper	Director	Buy	2,500	$4.65	$11,625.00

(Data available from 1/1/2013 forward)

Headlines

Latest Headlines for Celsion Corp. (NASDAQ:CLSN)

Date	Headline
	Keen Investors Find News on Celsion Corp. (NASDAQ:CLSN) - Duncan Research (NASDAQ:CLSN) www.duncanindependent.com - September 23 at 3:40 PM
	Under the Microscope, Zeroing in at Celsion Corp. (NASDAQ:CLSN) - Duncan Research (NASDAQ:CLSN) www.duncanindependent.com - September 22 at 4:25 PM
	Penny Stock Investors Take an Interest in Celsion Corp. (NASDAQ:CLSN) - Duncan Research (NASDAQ:CLSN) www.duncanindependent.com - September 21 at 8:19 AM
	Now Available: Celsion Corporation (CLSN) - Medical Equipment - Deals and Alliances Profile (NASDAQ:CLSN) reports.pr-inside.com - September 16 at 4:08 PM
	Company Update (NASDAQ:CLSN): Celsion Corporation Announces Positive DSMB Review of Phase 1b OVATION ... - Smarter Analyst (NASDAQ:CLSN) www.smarteranalyst.com - September 15 at 4:39 PM
	Celsion Corporation Announces Positive DSMB Review of Phase 1b OVATION Study in Ovarian Cancer (NASDAQ:CLSN) globenewswire.com - September 15 at 10:35 AM
	Celsion (CLSN) Reports DSMB Completed Safety Review of Data from Phase 1b OVATION Study in Ovarian Cancer (NASDAQ:CLSN) www.streetinsider.com - September 15 at 10:35 AM
	ThermoDox plus RFA may significantly improve survival of primary liver cancer patients (NASDAQ:CLSN) www.dotmed.com - September 14 at 4:21 PM
	Celsion Corporation Announces Independent NIH... (NASDAQ:CLSN) www.benzinga.com - September 13 at 9:07 AM
	Celsion (CLSN) Announces Substantial Data from Independent NIH Analysis of HEAT Study (NASDAQ:CLSN) www.streetinsider.com - September 13 at 9:07 AM
	ETF’s with exposure to Celsion Corp. : September 12, 2016 (NASDAQ:CLSN) www.capitalcube.com - September 12 at 4:07 PM
	Celsion (CLSN) Announces Substantial Data from Independent NIH Analysis of HEAT Study - StreetInsider.com (NASDAQ:CLSN) www.streetinsider.com - September 12 at 9:04 AM
	CELSION CORP Files SEC form 8-K, Change in Directors or Principal Officers (NASDAQ:CLSN) biz.yahoo.com - September 9 at 9:05 AM
	Sell-side is Weighing in on Celsion Corporation (NASDAQ:CLSN) Earnings - Frisco Fastball (NASDAQ:CLSN) friscofastball.com - September 8 at 5:13 AM
	Celsion Corporation to Present at Upcoming Investor Conferences - GlobeNewswire (press release) (NASDAQ:CLSN) globenewswire.com - September 7 at 8:05 AM
	Celsion Corporation to Present at Upcoming Investor Conferences (NASDAQ:CLSN) finance.yahoo.com - September 7 at 8:05 AM
	Stock in Review: Taking a Closer Look at Celsion Corporation (NASDAQ:CLSN) Shares - Post News (NASDAQ:CLSN) www.kentuckypostnews.com - September 2 at 9:05 AM
	ETF’s with exposure to Celsion Corp. : August 30, 2016 (NASDAQ:CLSN) www.capitalcube.com - August 30 at 4:17 PM
	ETF’s with exposure to Celsion Corp. : August 30, 2016 (NASDAQ:CLSN) www.capitalcube.com - August 30 at 4:17 PM
	Celsion Corporation (NASDAQ:CLSN) Is Expected To Post EPS Of $-0.12 - RealistInvestor.com (NASDAQ:CLSN) www.realistinvestor.com - August 29 at 9:32 PM
	CELSION CORP Financials (NASDAQ:CLSN) finance.yahoo.com - August 24 at 4:16 PM
	Crowd & Analysts Have Spoken: Celsion Corporation (NASDAQ:CLSN) Stock Update - Post News (NASDAQ:CLSN) www.kentuckypostnews.com - August 22 at 9:00 AM
	ETF’s with exposure to Celsion Corp. : August 19, 2016 (NASDAQ:CLSN) www.capitalcube.com - August 19 at 3:21 PM
	Celsion Corp. :CLSN-US: Earnings Analysis: Q2, 2016 By the Numbers : August 18, 2016 (NASDAQ:CLSN) www.capitalcube.com - August 18 at 4:19 PM
	Director of Celsion Corporation (NASDAQ:CLSN), Martinez Alberto R Jr, buys 5,000 shares worth $6,250 (NASDAQ:CLSN) empowerednews.net - August 18 at 11:05 AM
	Analysts See Celsion Corporation (NASDAQ:CLSN) Reporting EPS Of $-0.14 - RealistInvestor.com (NASDAQ:CLSN) www.realistinvestor.com - August 16 at 9:34 PM
	Celsion announces final overall survival data from ThermoDox HEAT study (NASDAQ:CLSN) www.dotmed.com - August 16 at 4:22 PM
	Zhejiang Hisun Pharmaceutical : Hisun Pharmaceutical H1 Net Down 45% (NASDAQ:CLSN) www.4-traders.com - August 16 at 8:59 AM
	Celsion (CLSN) Offers Updated ThermoDox HEAT Study Data; Notes Robust OS Results (NASDAQ:CLSN) www.streetinsider.com - August 16 at 8:59 AM
	Celsion liver cancer data underscores co's potential of its technology (NASDAQ:CLSN) www.proactiveinvestors.com - August 15 at 11:32 AM
	CELSION CORP Files SEC form 8-K, Results of Operations and Financial Condition, Financial Statements and Exhibits (NASDAQ:CLSN) biz.yahoo.com - August 15 at 11:32 AM
	Celsion Corporation Reports Second Quarter 2016 Financial Results and Provides Business Update (NASDAQ:CLSN) www.publicnow.com - August 15 at 11:32 AM
	Celsion Corporation and Zhejiang Hisun Pharmaceutical Company Sign Technology ... (NASDAQ:CLSN) finance.yahoo.com - August 10 at 5:20 AM
	Celsion (CLSN) Enters Expanded GEN-1 Partnership with Zhejiang Hisun Pharma - StreetInsider.com (NASDAQ:CLSN) www.streetinsider.com - August 9 at 5:15 PM
	Expanded Partnership Provides Capacity and Cost Structure Supporting Celsion's Global Commercial Strategy for GEN-1 (NASDAQ:CLSN) www.nasdaq.com - August 9 at 11:45 AM
	Celsion Corporation and Zhejiang Hisun Pharmaceutical Company Sign Technology Transfer, Manufacturing and Commercial Supply Agreement for the Development of its GEN-1 Immuno-Oncology Therapy (NASDAQ:CLSN) www.publicnow.com - August 9 at 11:45 AM
	Celsion Corporation to Hold Second Quarter 2016 Financial Results Conference Call on Monday, August 15, 2016 (NASDAQ:CLSN) www.publicnow.com - August 8 at 9:06 AM
	Gene Therapy (NASDAQ:CLSN) www.wealthdaily.com - July 28 at 12:45 PM
	Celsion : Announces Positive Data from the OVATION Study - An Immunotherapy Study of Newly Diagnosed Ovarian Cancer Patients (NASDAQ:CLSN) www.4-traders.com - July 26 at 4:10 PM
	Celsion announces positive data from OVATION study (NASDAQ:CLSN) www.dotmed.com - July 26 at 12:26 PM
	Celsion (CLSN) Announces Data from GEN-1 Phase 1b; One pCR Noted (NASDAQ:CLSN) www.streetinsider.com - July 25 at 9:01 PM
	Celsion Announces Positive Data from the OVATION Study - An Immunotherapy Study of Newly Diagnosed Ovarian Cancer Patients (NASDAQ:CLSN) www.publicnow.com - July 25 at 8:28 AM
	8:05 am Celsion announces data from the immunotherapy study of newly diagnosed ovarian cancer patients (NASDAQ:CLSN) finance.yahoo.com - July 25 at 8:05 AM
	Earnings Focus and Crowd Sourced Sentiment Review for Celsion Corporation (NASDAQ:CLSN) - TGP (NASDAQ:CLSN) telanaganapress.com - July 22 at 11:46 AM
	Insiders Increasing Positions in: Celsion Corp. (NASDAQ:CLSN) - Press Telegraph (NASDAQ:CLSN) presstelegraph.com - July 21 at 9:48 PM
	Celsion Corporation (NASDAQ:CLSN) Shorts Decreased by 39.49% After Short Covering - Consumer Eagle (NASDAQ:CLSN) www.consumereagle.com - July 20 at 5:24 PM
	Broker Outlook For Celsion Corporation (CLSN) - Fiscal Standard (NASDAQ:CLSN) www.fiscalstandard.com - July 20 at 5:24 PM
	ETF’s with exposure to Celsion Corp. : July 20, 2016 (NASDAQ:CLSN) www.capitalcube.com - July 20 at 12:16 PM
	Equity Roundup: Stock Performance Focus on Celsion Corporation (NASDAQ:CLSN) - Press Telegraph (NASDAQ:CLSN) presstelegraph.com - July 19 at 4:21 PM
	Celsion Corp. Realized Volatility Hits a Dropping Level - CML News (NASDAQ:CLSN) news.cmlviz.com - July 19 at 4:21 PM

Social

Celsion Corp. (NASDAQ:CLSN) Chart for Sunday, September, 25, 2016